Current Report Filing (8-k)
March 15 2023 - 4:04PM
Edgar (US Regulatory)
0001711754
false
0001711754
2023-03-15
2023-03-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 15, 2023
|
INMUNE BIO INC. |
|
|
(Exact name of registrant as specified in charter) |
|
Nevada |
|
001-38793 |
|
47-5205835 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of incorporation) |
|
|
|
Identification No.) |
225 NE Mizner Blvd., Suite 640, Boca Raton,
Florida 33432
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per shares |
|
INMB |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On March 15, 2023, INmune Bio
Inc. (the “Company”) is filing as Exhibit 99.1 to this Current Report on Form 8-K a slide deck that the Company intends to
use in a presentation. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no
admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The
information contained in the presentation is summary information that is intended to be considered in the context of the Company’s
Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release
or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in
this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the
filing of other reports or documents with the SEC, through press releases or through other public disclosure
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
99.1 |
|
Presentation |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMUNE BIO INC. |
|
|
Date: March 15, 2023 |
By: |
/s/ David Moss |
|
|
David Moss |
|
|
Chief Financial Officer |
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024